BRAF inhibitor trang 1 tải miễn phí từ TAILIEUCHUNG

"BRAF inhibitor" trang 1 - tải miễn phí từ Tailieuchung

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

12 43 1

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib

5 52 1

Complete clinical regression of a BRAF V600Emutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Complete clinical regression of a BRAF V600Emutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

5 40 1

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

7 25 1

Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care

Prognostic significance of BRAF and NRAS mutations in melanoma: A German study from routine care

12 28 1

Báo cáo hóa học:

Báo cáo hóa học: " Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032"

3 41 0

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

Granulomatosis with polyangiitis in a patient treated with dabrafenib and trametinib for BRAF V600E positive lung adenocarcinoma

5 75 0

Ifferential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

Ifferential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines

10 127 1

Efficacy of sorafenib in BRAF-mutated nonsmall-cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report

Efficacy of sorafenib in BRAF-mutated nonsmall-cell lung cancer (NSCLC) and no response in synchronous BRAF wild typehepatocellular carcinoma: A case report

5 60 1

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status

13 25 1

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

Effect of dabrafenib on melanoma cell lines harbouring the BRAFV600D/R mutations

3 30 1

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma

The clinical response to vemurafenib in a patient with a rare BRAFV600DK601 del mutation-positive melanoma

8 71 1

Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis

Comparative efficacy and safety of combination therapies for advanced melanoma: A network meta-analysis

10 36 1

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: Pooled analysis of clinical trials

6 35 0

Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiationinduced abdominal wall angiosarcoma with low-dose apatinib: A case report

Treatment of consistent BRAF/HRAS gene mutation and MYC amplification radiationinduced abdominal wall angiosarcoma with low-dose apatinib: A case report

6 74 0

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation

5 50 1

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting

Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting

13 46 0

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.